Blog
NHS general practice data, analysed
Occasional England-level analysis of the open datasets behind the Arjus dashboards — QOF, CVDPREVENT and the wider NHS primary care publications — written for the practices and PCN teams who have to act on them. Practice-level versions of these numbers live in the practice summary and the monthly email digest.
The year-long waits are vanishing. The six-month surgical waits are not.
9 September 2026 · Dr Yogasakaran Arjuna
England and ICB-level analysis of three years of waiting-times data to June 2026: the list is 600,000 below its 2023 peak and year-long waits have fallen 45% in twelve months — but patients admitted for surgery still typically wait around six months, the queue-snapshot median hides it, and the gap between the best and worst ICBs runs five-fold on the admitted wait.
The registers grew by 1.88 million. The population didn't.
31 August 2026 · Dr Yogasakaran Arjuna
England-level analysis of the QOF 2025/26 publication: 1.88 million more register entries on a registered population that actually shrank. Hypertension crosses ten million, heart failure and pre-diabetes grow fastest, asthma stalls — and osteoporosis is the only register that shrank. All 21 registers, year on year, with the caveats that matter when reading recorded prevalence.
Neighbourhoods, SNPs and MNPs: a plain-English guide
27 August 2026 · Dr Yogasakaran Arjuna
A year on from the 10 Year Health Plan, neighbourhood health has gone from slogan to consultation document. What SNP and MNP contracts actually are, how the local variation of the PCN DES fits in, what's protected, who might sit above your PCN at scale — and the consultation deadline of 10 September 2026 that general practice shouldn't miss. Fully referenced from NHS England, DHSC, Pulse and HSJ.
Read the guideCVDPREVENT: England, to March 2026
25 August 2026 · Dr Yogasakaran Arjuna
The March 2026 extraction is the first full quarter to show what happens when a fifth of QOF is torn up and re-aimed at cardiovascular prevention: blood pressure control hit a record high, lipid optimisation accelerated, smoking-cessation support fell off a cliff — and seven new indicators set the national baseline for SGLT2 inhibitors.